Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Double-Blind, Placebo-Controlled, Parallel-Group, 36-Week, 2-Arm Trial With an Open-Label Extension Phase to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer's Disease

NCT06125951 is registered in ClinicalTrials.gov with Actinogen Medical as lead sponsor.

NCT NCT06125951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06125951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Double-Blind, Placebo-Controlled, Parallel-Group, 36-Week, 2-Arm Trial With an Open-Label Extension Phase to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer's Disease
Lead sponsor
Actinogen Medical
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
April 12, 2024
Completion date
February 29, 2028
Enrollment
247 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, dementia moderate, dementia, mild